Considerations in the design of clinical trials for cognitive aging

Eric M. Reiman, Roberta Diaz Brinton, Russell Katz, Ronald Carl Petersen, Selam Negash, Dan Mungas, Paul S. Aisen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

What will it take to develop interventions for the treatment of age-related cognitive decline? Session V of the Summit provided perspectives on the design of clinical trials to evaluate promising but unproven interventions, and some of the steps needed to accelerate the discovery and evaluation of promising treatments. It considered strategies to further characterize the biological and cognitive changes associated with normal aging and their translation into the development of new treatments. It provided regulatory, scientific, and clinical perspectives about neurocognitive aging treatments, their potential benefits and risks, and the strategies and endpoints needed to evaluate them in the most rapid, rigorous, and clinically meaningful way. It considered lessons learned from the study of Alzheimer's disease, the promising roles of biomarkers in neurocognitive aging research, and ways to help galvanize the scientific study and treatment of neurocognitive aging.

Original languageEnglish (US)
Pages (from-to)766-772
Number of pages7
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume67 A
Issue number7
DOIs
StatePublished - Jun 15 2012

Fingerprint

Alzheimer Disease
Biomarkers
Clinical Trials
Research
Cognitive Aging
Cognitive Dysfunction

Keywords

  • Aging
  • Clinical trials
  • Cognition

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Considerations in the design of clinical trials for cognitive aging. / Reiman, Eric M.; Brinton, Roberta Diaz; Katz, Russell; Petersen, Ronald Carl; Negash, Selam; Mungas, Dan; Aisen, Paul S.

In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 67 A, No. 7, 15.06.2012, p. 766-772.

Research output: Contribution to journalArticle

Reiman, Eric M. ; Brinton, Roberta Diaz ; Katz, Russell ; Petersen, Ronald Carl ; Negash, Selam ; Mungas, Dan ; Aisen, Paul S. / Considerations in the design of clinical trials for cognitive aging. In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2012 ; Vol. 67 A, No. 7. pp. 766-772.
@article{3eb042fe1ded40c3992e4eead1e4439a,
title = "Considerations in the design of clinical trials for cognitive aging",
abstract = "What will it take to develop interventions for the treatment of age-related cognitive decline? Session V of the Summit provided perspectives on the design of clinical trials to evaluate promising but unproven interventions, and some of the steps needed to accelerate the discovery and evaluation of promising treatments. It considered strategies to further characterize the biological and cognitive changes associated with normal aging and their translation into the development of new treatments. It provided regulatory, scientific, and clinical perspectives about neurocognitive aging treatments, their potential benefits and risks, and the strategies and endpoints needed to evaluate them in the most rapid, rigorous, and clinically meaningful way. It considered lessons learned from the study of Alzheimer's disease, the promising roles of biomarkers in neurocognitive aging research, and ways to help galvanize the scientific study and treatment of neurocognitive aging.",
keywords = "Aging, Clinical trials, Cognition",
author = "Reiman, {Eric M.} and Brinton, {Roberta Diaz} and Russell Katz and Petersen, {Ronald Carl} and Selam Negash and Dan Mungas and Aisen, {Paul S.}",
year = "2012",
month = "6",
day = "15",
doi = "10.1093/gerona/gls124",
language = "English (US)",
volume = "67 A",
pages = "766--772",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Considerations in the design of clinical trials for cognitive aging

AU - Reiman, Eric M.

AU - Brinton, Roberta Diaz

AU - Katz, Russell

AU - Petersen, Ronald Carl

AU - Negash, Selam

AU - Mungas, Dan

AU - Aisen, Paul S.

PY - 2012/6/15

Y1 - 2012/6/15

N2 - What will it take to develop interventions for the treatment of age-related cognitive decline? Session V of the Summit provided perspectives on the design of clinical trials to evaluate promising but unproven interventions, and some of the steps needed to accelerate the discovery and evaluation of promising treatments. It considered strategies to further characterize the biological and cognitive changes associated with normal aging and their translation into the development of new treatments. It provided regulatory, scientific, and clinical perspectives about neurocognitive aging treatments, their potential benefits and risks, and the strategies and endpoints needed to evaluate them in the most rapid, rigorous, and clinically meaningful way. It considered lessons learned from the study of Alzheimer's disease, the promising roles of biomarkers in neurocognitive aging research, and ways to help galvanize the scientific study and treatment of neurocognitive aging.

AB - What will it take to develop interventions for the treatment of age-related cognitive decline? Session V of the Summit provided perspectives on the design of clinical trials to evaluate promising but unproven interventions, and some of the steps needed to accelerate the discovery and evaluation of promising treatments. It considered strategies to further characterize the biological and cognitive changes associated with normal aging and their translation into the development of new treatments. It provided regulatory, scientific, and clinical perspectives about neurocognitive aging treatments, their potential benefits and risks, and the strategies and endpoints needed to evaluate them in the most rapid, rigorous, and clinically meaningful way. It considered lessons learned from the study of Alzheimer's disease, the promising roles of biomarkers in neurocognitive aging research, and ways to help galvanize the scientific study and treatment of neurocognitive aging.

KW - Aging

KW - Clinical trials

KW - Cognition

UR - http://www.scopus.com/inward/record.url?scp=84863706212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863706212&partnerID=8YFLogxK

U2 - 10.1093/gerona/gls124

DO - 10.1093/gerona/gls124

M3 - Article

C2 - 22573913

AN - SCOPUS:84863706212

VL - 67 A

SP - 766

EP - 772

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 7

ER -